GLP-1 “weight loss” drugs like Ozempic and Zepbound are revolutionary medical treatments. In a study published this week in PLOS Global Public Health, my co-authors and I present the current evidence on how this new class of pharmaceuticals is also a powerful social and psychological intervention, reshaping everyday life far beyond the clinic.
Bringing together teams of social scientists working in places as diverse as Japan, Denmark, Brazil, and the United States, we were able to pool our data to identify important trends. These reflect changes in how people relate to their doctors, to others, and to themselves that are emerging in strikingly similar ways across very different contexts.
Identifying what we do know, based on research with users, has also clarified what we don’t know—but urgently need to—if we are to make GLP-1 drugs safer. Here are some of the fundamental and concerning global trends we have identified.
Feeling “Normal” Can Come With Emotional Costs
Those who lose a lot of weight often describe an intense sense of relief and happiness at finally “feeling normal” in their bodies. They also report being treated better at work and in social settings.
At the same time, this improved treatment can sharpen awareness of how devalued they were before they lost significant weight—often a psychologically painful and harmful realization. This highlights the importance of psychological support when people undergo rapid and substantial weight loss.
Demand Is Increasingly Driven by Weight Anxiety, Not Medical Need
We observe very strong demand among people who are medically “healthy” but fearful of weight gain. Even in countries like Japan, where obesity rates are very low, people continue to seek these drugs.
New direct-to-consumer efforts by telehealth companies to tap into weight anxiety are accelerating a shift toward the use of GLP-1 drugs as cosmetic products, likely worsening weight-related stigma. Examples appearing in social media advertisements in the U.S. include the promise of becoming “bikini-ready.” This adds even greater urgency to understanding the long-term health and psychological effects of using these drugs across diverse populations, including among users without a history of very high body weight who nonetheless have high levels of weight-related anxiety.
People Tolerate Remarkable Levels of Discomfort and Sacrifice
Users frequently endure nausea, vomiting, dizziness, fatigue, and headaches that significantly disrupt daily life. Some reorganize work schedules, avoid social events, or call in sick rather than skip a dose.
Financial sacrifices are also common, with people draining savings, delaying retirement, or changing jobs to maintain insurance coverage. We need more real-world data on how these tradeoffs affect long-term health and well-being, given how disruptive simply accessing the drugs is to many users’ day-to-day lives.
Dosing Practices Diverge From Medical Advice
Across sites, people routinely adjust dosing schedules, count clicks on injection pens, space out injections, or stop and restart treatment. These strategies are developed in response to cost, shortages, and social media, rather than sound medical advice.
Most users report learning about GLP-1 drugs from TikTok, Reddit, Instagram, or local online platforms. These spaces can offer emotional support and practical advice, but they also circulate misinformation and normalize risky practices.
While these factors can give patients a sense of greater control over their health, they also amplify concerns about limited data on off-label use and unsupervised dosing. Greater attention to often chaotic real-world use patterns is essential for accurately assessing drug side effects and safety.
Appetite Suppression Blurs Into Disordered Eating
Users often celebrate losing interest in food and describe relief from constant thoughts about eating, sometimes referred to as the quieting of “food noise.” However, many of the same behaviors associated with low appetite and food avoidance would be considered disordered eating in thinner bodies.
One user insightfully called the drugs “doctor-approved anorexia.” This creates a gray zone that complicates eating-disorder risk, prevention, and recovery. This is especially concerning as a barely-researched space in which substantial harms from the drugs are likely to accrue.
Final Thoughts
We now have solid global evidence that GLP-1 receptor agonists are not just changing bodies—they are changing how people understand and organize their daily lives, including how they act on ideas of medical responsibility and risk. Addressing their impact and ensuring user safety requires understanding these drugs as technologies that are reshaping both sense of self and society, not merely as pharmaceuticals that allow rapid weight loss.
link